QIAGEN N.V. is a Netherlands-based holding company and the leading global provider of Sample to Insight solutions that transform biological samples into valuable molecular insights. Founded in Germany in 1984, it specializes in technologies for isolating and processing DNA, RNA, and proteins from blood, tissue, and other materials, alongside assay technologies, bioinformatics software, and automation workflows for analysis. The company serves over 500,000 customers worldwide across molecular diagnostics for human healthcare, applied testing in forensics, veterinary, and food safety, pharmaceutical and biotech R&D, and academic life sciences research. With more than 500 core products including disposable kits, automated workstations, and testing agents, QIAGEN operates in over 130 countries, with key locations in Venlo, Netherlands; Hilden, Germany; and regional hubs in the US, China, and Singapore. Employing thousands globally and led by CEO Thierry Bernard, QIAGEN plays a pivotal role in advancing scientific discovery, disease diagnosis, and personalized medicine through innovative molecular tools. Its extensive acquisition history, including companies like Digene, Cellestis, and Verogen, has expanded its capabilities in diagnostics and bioinformatics. QIAGEN N.V. significantly contributes to the life sciences and healthcare sectors by enabling faster, more reliable molecular analysis.